NKTR
Nektar Therapeutics · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -7.7% ·
share flow -30.0% ·
net new positions -8.3%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 78 | +13 | 18.28M | $1.28B | +22 | −8 |
| Q1 2026 | 67 | +13 | 13.34M | $957.94M | +15 | −3 |
| Q4 2025 | 55 | +1 | 8.38M | $354.26M | +2 | — |
| Q3 2025 | 15 | 0 | 5.00M | $284.66M | +2 | −2 |
| Q2 2025 | 12 | -1 | 3.08M | $79.53M | +1 | −2 |
| Q1 2025 | 10 | -1 | 25.55M | $17.36M | — | −1 |
| Q4 2024 | 11 | 0 | 24.86M | $23.13M | — | — |
| Q3 2024 | 10 | +2 | 27.79M | $36.10M | +2 | — |
| Q2 2024 | 8 | — | 27.40M | $33.98M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 729.49K | — | $18.85M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | The Vanguard Group ✦ (passive) | 729.49K | — | $18.85M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Millennium Management ✦ | 649.03K | +325.4% | $16.77M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 4 | AQR Capital Management ✦ | 427.87K | +76.3% | $11.06M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | AQR Capital Management ✦ | 427.87K | +76.3% | $11.06M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | AQR Capital Management ✦ | 427.87K | +76.3% | $11.06M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 427.87K | +76.3% | $11.06M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | BlackRock ✦ (passive) | 415.23K | — | $10.73M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | BlackRock ✦ (passive) | 415.23K | — | $10.73M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | BlackRock ✦ (passive) | 415.23K | — | $10.73M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | BlackRock ✦ (passive) | 415.23K | — | $10.73M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | BlackRock ✦ (passive) | 415.23K | — | $10.73M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | BlackRock ✦ (passive) | 415.23K | — | $10.73M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | BlackRock ✦ (passive) | 415.23K | — | $10.73M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | PRIMECAP Management ✦ | 299.72K | -16.0% | $7.74M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 16 | Renaissance Technologies ✦ | 247.06K | -21.2% | $6.38M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 17 | Geode Capital Management ✦ (passive) | 132.37K | -50.5% | $3.42M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 18 | Geode Capital Management ✦ (passive) | 132.37K | -50.5% | $3.42M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 19 | Two Sigma Investments ✦ | 79.39K | -17.0% | $2.05M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 20 | State Street Global Advisors ✦ (passive) | 50.10K | -76.9% | $1.29M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 21 | T. Rowe Price ✦ | 17.80K | +4.1% | $460,000 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 22 | Fidelity (FMR) ✦ | 15.28K | — | $394,732 | 0.0% | n/c | 1 | SEC ↗ |
| 23 | Marshall Wace ✦ | 14.20K | New | $366,928 | 0.0% | New | 1 | SEC ↗ |
| 24 | Marshall Wace ✦ | 14.20K | New | $366,928 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $366,928 | 0.0% |
| Marshall Wace | $366,928 | 0.0% |
Exited
| Citadel Advisors | $334,013 | was 0.0% |
| D. E. Shaw & Co. | $78,329 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 13.40K shares, $964 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 418 sh · $30,088
Officer · 186 sh · $13,388
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology